|Articles|October 1, 2001
- Pharmaceutical Executive-10-01-2001
- Volume 0
- Issue 0
National Crisis Supercedes Coverage Debate
Efforts to craft a Medicare pharmacy benefit may be sidelined by repercussions from the September attack.
Advertisement
Articles in this issue
almost 25 years ago
National Crisis Supercedes Coverage Debatealmost 25 years ago
PBMs: Merck-Medco in the Hot Seatalmost 25 years ago
A Five-Year Forecast: Clear Seas Ahead?almost 25 years ago
Weak Bones, Strong Marketalmost 25 years ago
Approvals: Novartis’ Silver Liningalmost 25 years ago
Pfizer and others Pitch Inalmost 25 years ago
Oncology: EMEA Approval Lagsalmost 25 years ago
Illegal Sales in Indiaalmost 25 years ago
Health Plan Premiums: Pharma Takes the Blamealmost 25 years ago
Little Elan Becomes a Big DealAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Significance of FDA’s First Warning Letter for Inappropriate Use of AI
2
Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion
3
Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance
4
M&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo
5